Public awareness and HPV vaccination rates remain low among American adults

The human papillomavirus (HPV), a common sexually transmitted infection, accounts for 70% of all throat cancers, according to the National Cancer Institute.

Immunovant’s plans for autoimmune asset; Wall Street worries about Moderna’s RSV candidate

Plus, news about Novo Holdings, Gritstone Bio, Invivyd and Science 37: Immunovant outlines big plans for its autoimmune program: The biotech now expects to launch

February 13, 2024

Baseless fears about fluoride are going mainstream

Good morning! I’m taking some time off to retreat to the woods, so you’ll be hearing from some of my colleagues for a few days.

November 13, 2024

Tepotinib Gains Full Approval for Metastatic NSCLC

The FDA transitioned the small-molecule inhibitor tepotinib (Tepmetko) from accelerated to full approval for metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping

February 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.